H Lundbeck AS (LUNAM)

Vienna
Currency in EUR
4.53
-0.11(-2.37%)
Closed
LUNAM Scorecard
Full Analysis
Has raised its dividend for 3 consecutive years
Fair Value
Day's Range
4.534.64
52 wk Range
3.725.57
Key Statistics
Edit
Bid/Ask
4.48 / 4.57
Prev. Close
4.64
Open
4.64
Day's Range
4.53-4.64
52 wk Range
3.72-5.57
Volume
-
Average Volume (3m)
3.67K
1-Year Change
15.77%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
LUNAM Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a low P/E ratio relative to near-term earnings growth
Show more

H Lundbeck AS Company Profile

H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson’s disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson’s disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. The company was founded in 1915 and is headquartered in Valby, Denmark.

Employees
5707
Market
Austria

Compare LUNAM to Peers and Sector

Metrics to compare
LUNAM
Peers
Sector
Relationship
P/E Ratio
13.1x17.9x−0.6x
PEG Ratio
0.340.060.00
Price/Book
1.6x4.3x2.6x
Price / LTM Sales
1.9x3.9x3.1x
Upside (Analyst Target)
-14.5%51.2%
Fair Value Upside
Unlock7.6%8.7%Unlock

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 3.17
Dividend Yield
-
Annualised payout
-
5-Years Growth
-
Growth Streak

Earnings

Latest Release
-
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

FAQ

What Is the H Lundbeck AS (LUNAM) Stock Price Today?

The H Lundbeck AS stock price today is 4.53

What Stock Exchange Does H Lundbeck AS Trade On?

H Lundbeck AS is listed and trades on the Vienna stock exchange.

What Is the Stock Symbol for H Lundbeck AS?

The stock symbol for H Lundbeck AS is "LUNAM."

Does H Lundbeck AS Pay Dividends? What’s The Current Dividend Yield?

The H Lundbeck AS dividend yield is 2.81%.

What Is the H Lundbeck AS Market Cap?

As of today, H Lundbeck AS market cap is 5.35B.

What is H Lundbeck AS Earnings Per Share?

The H Lundbeck AS EPS is 3.17.

From a Technical Analysis Perspective, Is LUNAM a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.